Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Earlier Diagnosis of Melanoma May Soon Become Possible Using T-Rays

By BiotechDaily International staff writers
Posted on 23 Sep 2013
Image: Layers of skin can be probed with terahertz rays in search of signs of skin cancer at its earliest stages of development (Photo courtesy of the [US] National Cancer Institute).
Image: Layers of skin can be probed with terahertz rays in search of signs of skin cancer at its earliest stages of development (Photo courtesy of the [US] National Cancer Institute).
New imaging technology has great potential to diagnose cancer at its earliest and most treatable stages.

Anis Rahman, PhD, president and chief technology officer of Applied Research & Photonics (Harrisburg, PA, USA), reported that malignant melanoma, the most lethal type of skin cancer, begins in pigment-producing cells located in the deepest part of the epidermis (the outer layer of the skin). Biochemical alterations are key characteristics of cancer occur in the melanocytes a long time before mole-like melanomas appear on the skin.

“Terahertz radiation is ideal for looking beneath the skin and detecting early signs of melanoma,” Dr. Rahman said. “T-rays are different from X-rays, which are ‘ionizing’ radiation that can cause damage. T-rays are a form of nonionizing radiation, like ordinary visible light, but they can be focused harmlessly below into the body and capture biochemical signatures of events like the start of cancer.”

T-rays occupy a position in the spectrum of electromagnetic radiation, which includes visible light and X-rays, between microwaves and infrared rays. One of the benefits of T-rays is that they penetrate only a few millimeters through skin, cloth, and other nonmetallic material.

Dr. Rahman’s research on T-rays was made through donated samples of human skin, suggesting that the technology could be valuable in diagnosing melanoma. In addition to developing T-rays for cancer diagnostics, Dr. Rahman’s team has effectively utilized them to measure the real-time absorption rates and penetration in the outer layer of skin of topically applied drugs—measurements that until now had not been possible.

Dr. Rahman presented his findings at a symposium held at the annual American Chemical Society (ACS) 2013 meeting, held September 11, 2013, in Indianapolis (IN, USA).

Related Links:
Applied Research & Photonics



view channel
Image: Micrograph showing immunofluorescence of skin differentiation markers for basal keratinocytes (Photo courtesy of Dr. Russ Carstens, University of Pennsylvania).

Alternate Splicing Proteins Critically Linked to Skin and Organ Development

Two proteins that regulate alternative splicing in epithelial cells have been linked to the proper development of the skin and protective layers that surround other organs in the body. Two steps are... Read more

Drug Discovery

view channel
Image: Endoscopic image of a bowel section known as the sigmoid colon afflicted with ulcerative colitis. The internal surface of the colon is blotchy and broken in places (Photo courtesy of Wikimedia Commons).

Orally Delivered Curcumin-Loaded Microparticles Effectively Treat Mouse Model of Ulcerative Colitis

Microparticles (MPs) loaded with the efficient anti-inflammatory agent curcumin were found to effectively treat a mouse model of ulcerative colitis. Ulcerative colitis is a chronic relapsing disease... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


view channel

Collaboration Agreement to Boost Discovery of Fully Human Antibodies for Therapeutic Use

The discovery of fully human antibodies for therapeutic use will be boosted by a recently announced collaboration between a major university research center and a dynamic biopharmaceutical development company. Regeneron Pharmaceuticals, Inc. (Tarrytown, New York, USA) and The Experimental Therapeutics Institute (ETI)... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.